Evaluation of Nilotinib In Patients With Advanced Gastrointestinal Stromal Tumor (GIST)
Status:
Completed
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
This study will assess time-to-disease progression in patients with advanced gastrointestinal
stromal tumor (GIST) previously treated with imatinib ≥600 mg.